ダウンロード数 : ?
ファイル
言語
英語
著者
Okimoto, Tamio Division of Medical Oncology & Respiratory Medicine, Department of Internal Medicine, Shimane University, Japan
内容記述(抄録等)
A 40-year-old Japanese man with advanced pulmonary adenocarcinoma harboring anaplastic lymphoma kinase (ALK)-rearranged was administered the selective ALK inhibitor ceritinib as a third-line treatment and continued treatment for nine months. After fourth-line treatment, we performed rechallenge with ceritinib as a fifth-line treatment. On day 54 after rechallenge, the patient developed acutely deteriorating dyspnea. Chest computed tomography showed extensive ground-glass opacities. We diagnosed him with ceritinib-induced interstitial lung disease (ILD) and initiated methylprednisolone pulse therapy. To our knowledge, this is the first report of ceritinib-induced ILD in a Japanese patient. Since it may newly emerge with rechallenge therapy, close attention is necessary.
主題
ceritinib
interstitial lung disease
anaplastic lymphoma kinase
adverse event
掲載誌名
Internal medicine
59
2
開始ページ
253
終了ページ
256
ISSN
0918-2918
ISSN(Online)
1349-7235
発行日
2019
DOI
出版者
一般社団法人 日本内科学会
出版者ヨミ
イッパン シャダンホウジン ニホン ナイカ ガッカイ
出版者別表記
The Japanese Society of Internal Medicine
資料タイプ
学術雑誌論文
ファイル形式
PDF
著者版/出版社版
著者版
業績ID
e38014
部局
医学部
このエントリーをはてなブックマークに追加